

Contents

List of contributors	vii
Preface	ix
Acknowledgements	xii
Part 1 Epidemiology, genetics and screening	
1 Colorectal cancer epidemiology <i>Michael Langman and Peter Boyle</i>	3
2 Molecular basis for risk factors in colorectal cancer – genetic syndromes, adenomatous colorectal polyps and ulcerative colitis <i>Robert Hardy</i>	13
3 Cancer genetics and colorectal cancer: understanding how current data should be influencing routine clinical practice <i>Trevor Cole, Christopher Weiner and H Vicky Sleightholme</i>	33
4 Effectiveness of colorectal cancer screening <i>Wendy S Atkin</i>	55
Part 2 Evidence and opinion for medical intervention	
5 Scientific evidence and expert clinical opinion for adjuvant chemotherapy after curatively resected colon cancer <i>Nick Maisey and Mark Hill</i>	71
6 Scientific evidence and expert clinical opinion for the management of advanced disease <i>D Alan Anthoney and Matthew T Seymour</i>	85
7 Scientific evidence and expert clinical opinion for the optimal use of the oral fluoropyrimidines: combination therapy versus monotherapy <i>Paul Mainwaring</i>	101
8 Novel strategies for the treatment of colorectal cancer <i>Daniel Hochhauser</i>	113
Part 3 Rectal cancer	
9 Total mesorectal excision as a standard surgical procedure: the evidence base for improved clinical outcome <i>Bill Heald</i>	125
10 Local staging of rectal cancer: the clinical effectiveness of high-resolution MRI <i>Gina Brown and Ceri J Phillips</i>	131

vi Contents

11	Current thinking on the utility of preoperative chemoradiation <i>David Sebag-Montefiore</i>	149
----	---	-----

Part 4 NHS policy and colorectal cancer services

12	Strategies for the efficient management of all patients with lower gastrointestinal symptoms to achieve effective diagnosis of colorectal cancer <i>Michael R Thompson, ET Swarbrick, BG Ellis, I Heath, L Faulds Wood, C Coles and WS Atkin</i>	165
----	---	-----

	<i>Index</i>	189
--	--------------	-----

Scientific evidence and expert clinical opinion for the management of advanced colorectal cancer by combination chemotherapy

D Alan Anthony and Matthew T Seymour

Introduction

For most of the last three decades, the development of chemotherapy for colorectal cancer has been a process of meticulous optimisation of single-agent therapy with 5-fluorouracil (5FU). Within this straightjacket, considerable progress has been made. Indeed, 5FU has turned out to be a more active and versatile drug than first imagined: it has a well-established evidence base for benefit in both the adjuvant and palliative setting, and when used well it lacks many of the distressing side effects of other cytotoxic drugs.

However, 5FU also has many limitations. For around a third of patients not even temporary stabilisation of disease is obtained, and over the past 10 years it has become clear that even the most active 5FU regimens, when subjected to the rigours of well-conducted, externally reviewed, multicentre, phase III trials, produce WHO objective partial or complete responses in fewer than 30% of patients.

In the early 1980s, Goldie and Coldman (1984) and others (Dexter & Leith 1986) developed models of tumour growth and response to chemotherapy incorporating the concepts of genetic and phenotypic instability, with the emergence of drug-resistant clones during treatment. Goldie and Coldman predicted that the results of chemotherapy would be improved by the use of concurrent or alternating drug schedules, provided that the individual agents were (1) independently active and (2) non-cross resistant. These ideas have underpinned the development of combination chemotherapy for most cancers, but could not be applied or tested in colorectal cancer because only one active agent, 5FU, was available.

At last, this situation is changing. Recent years have seen the arrival of two new drugs, oxaliplatin and irinotecan, each with the properties of independent activity and non-cross resistance, which are prerequisites for combination therapy in the Goldie–Coldman model. In addition, new evidence has emerged for an old drug, mitomycin, suggesting that it, too, may have a role in combination chemotherapy for colorectal cancer.

The rapid burgeoning of knowledge on the cellular and molecular basis of carcinogenesis and metastasis has held the promise of developing drugs targeted to specific components of the pathways involved. A wide range of agents is currently




Figure 6.4 General schema for trials of first-line combination chemotherapy.

Table 6.1 Summarised results of first-line 5FU/LV ± irinotecan, oxaliplatin, mitomycin C, phase III randomised trials in advanced colorectal cancer

Reference	Treatment	n	RR (PR + CR) (%)	Median PFS (months)	Median OS (months)
Saltz <i>et al.</i> (2000)	Mayo 5-day 5FU/FA	219	21	4.3	12.6
	vs weekly 5FU/FA/	225	($p = 0.001$)	($p = 0.004$)	($p = 0.04$)
	irinotecan vs weekly irinotecan	223	39 18	7.0 4.2	14.8 12.0
Douillard <i>et al.</i> (2000)	5FU/FA (LV5FU2 or AIO) vs same	187 198	23 ($p < 0.001$)	19 weeks ($p < 0.001$)	14.1 ($p = 0.031$)
	5FU/FA + irinotecan		41	29 weeks	17.4
De Gramont <i>et al.</i> (2000)	5FU/FA (LV5FU2)	210	22	26 weeks	14.7
	vs same 5FU/FA + oxaliplatin	210	($p < 0.0001$) 50	(NS) 36 weeks	($p = 0.0003$) 16.2
Giacchetti <i>et al.</i> (2000)	5FU/FA (chrono)	100	16 ^a	6.1	19.9
	vs same 5FU/FA + oxaliplatin	100	($p < 0.0001$) 53 ^a	($p < 0.05$) 8.7	(NS) 19.4
Ross <i>et al.</i> (1997)	Protracted infusion 5FU vs same 5FU + mitomycin	100 100	38 ($p = 0.024$) 54	23 weeks ($p = 0.033$) 34 weeks	($p = 0.033$)*

CR, complete response; OS, overall survival; PFS, progression-free survival; PR, partial response; RR, response rate.

*Not significant in the original paper. Updated analysis: Price *et al.* (1999).

^aIncludes confirmed as well as unconfirmed responses.

The design did not quite conform to the scheme in Figure 6.4, because the 5FU/FA schedule in the control arm (the Mayo clinic 5-day monthly schedule) differed from

- Fong TA, Shawver LK, Sun L *et al.* (1999). SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. *Cancer Research* **59**, 99–106
- Garufi C, Brienza S, Pugliese P *et al.* (2000). Overcoming resistance to chronomodulated 5-Fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. *Anticancer Drugs* **11**, 495–501
- Gately S (2000). The contribution of cyclooxygenase-2 to tumour angiogenesis. *Cancer and Metastasis Reviews* **19**, 19–27
- Giacchetti S, Perpoint B, Zidani R *et al.* (2000). Phase III multicentre randomised trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer. *Journal of Clinical Oncology* **18**, 136–147
- Goldie J & Coldman A (1984). The genetic origin of drug resistance in neoplasms: implications for systemic therapy. *Cancer Research* **44**, 3643–3653
- Gordon MS, Margolin K, Talpaz M *et al.* (2001). Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. *Journal of Clinical Oncology* **19**, 843–850
- Hartmann JT, Harstrick A, Daikeler T *et al.* (1998). Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. *Anti-Cancer Drugs* **9**, 427–431
- Kargman SL, O'Neill GP, Vickers PJ *et al.* (1995) Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. *Cancer Research* **55**, 2556–2559
- Kumar H, Heer K, Lee PW (1998). Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. *Clinical Cancer Research* **14**, 1279–1285
- Levi F, Misset JL, Brienza S *et al.* (1992). A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. *Cancer* **69**, 893–900
- Machover D, Diaz-Rubio E, De Gramont A *et al.* (1996). Two consecutive phase II studies of oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. *Annals of Oncology* **7**, 95–98
- Maindrault-Goebel F, De Gramont A, Louvet C *et al.* (2000). Evaluation of oxaliplatin dose-intensity with the bimonthly 48hr leucovorin and 5-fluorouracil regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). *Annals of Oncology* **11**, 1477–1483
- Margolin K, Gordon MS, Holmgren E *et al.* (2001). Phase 1b trial of i.v. rhuMAb to VEGF in combination with chemotherapy in patients with advanced cancer. *Journal of Clinical Oncology* **19**, 851–856
- Mayer A, Takimoto M, Fritz E *et al.* (1993). The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor and mdr gene expression in colorectal cancer. *Cancer* **71**, 2454–2460
- Miller LL, Elfring GL, Hannah AL *et al.* (2001). Efficacy results of a phase I/II study of SU5416 (S)/5-fluorouracil (F)/Leucovorin(L) relative to results in random subsets of similar patients (Pts) from a phase III study of Irinotecan (C)/F/L or F/L alone in the therapy of previously untreated metastatic colorectal cancer (MCRC). *Proceedings of The American Society of Clinical Oncology* **20**, 571 (Abstr)